Welcome to Volume 10, Issue #1 (JANUARY 12, 2011) of Pharma Marketing News.
This article summarizes Eli Lilly's European experience using TeleWeb e-detailing, which combines a personal sales rep phone call with Web site surfing.
Welcome to Volume 10, Issue #2 (JANUARY 19, 2011) of Pharma Marketing News.
Public health officials cannot depend upon their noses to make important decisions. They need actionable real time data. How do they get it?
Pharma social networking sites like Facebook and YouTube may lack patient-centered information and can also be sources of misleading information that could potentially do more harm than good.
Pharma marketers save a bundle repurposing videos for Youtube. They save even more money by hiring real patients to play themselves in these videos! Patients are natural method actors, having actually experienced what they portray. But they are prone to over emote!
The Supreme Court has agreed to decide whether drug companies have to pay their sales representatives for working overtime hours, a question that could have considerable financial impact on the industry. The question before the court in case CHRISTOPHER V. SMITHKLINE BEECHAM CORP is whether or not pharmaceutical sales representatives are exempt from overtime pay under the 'outside sales' exemption of the Fair Labor Standards Act of 1938. If the Supreme Court rules that pharma sales reps are NOT exempt, some sales reps worry that they will become
Welcome to Volume 10, Issue #17 (10 NOVEMBER 2011) of Pharma Marketing News.
From the Audition in the Press to TV, Web, and Print Advertising. Pfizer and Amgen demonstrate how to launch a branded spokesperson campaign starting from a bit of over-the-top unregulated press relations to fully regulated TV, print, and Web advertising. It must be costing a mint!
The authors of a physician survey published in the November 8, 2010, issue of Archives of Internal Medicine conclude 'given that 83.8% of physicians have PIRs, it is clear that industry still has substantial financial links with the nation's physicians. These findings support the ongoing need for a national system of disclosure of PIRs [Physician-Drug Industry Relationships].' Such a system is part of the Physician Sunshine Law, which is scheduled to go into effect in 2012 with public disclosure of payments scheduled to begin September, 2013.